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Appropriate ECMO Screening
Protocols for Critically-Ill Patients
During COVID-19
Hudson Carter, Michael Baram MD*, Nawar Al-Rawas MD

What is ECMO?
•

An intervention that provides intense
cardiopulmonary support

•

Advantages of use in COVID-19
patients
– Direct pulmonary artery flow improves
oxygenation and ventilation
– Early mobility after removal
– Minimal cannula-associated
complications or revisions
– Support of right side of heart in case
of right ventricular dysfunction

ECMO Throughout the
COVID-19 Pandemic
•
•
•

Early data suggested a possible mortality
rate >90%
Currently 3,041 COVID-19 confirmed
patients have been treated with ECMO
Independent risk factors
– Age, immunocompromised state, chronic
respiratory disease, pre-ECMO cardiac
arrest, degree of hypoxemia

•

3 categories for guidelines
– Recommended: technique/intervention is
beneficial
– Not recommended: technique/intervention
is not beneficial or harmful
– Consider: possibly beneficial or use caution
when utilizing

Objectives
• Research Question
– Are the correct criteria being implemented for the screening of
ECMO patients based on resources during COVID-19?

• Hypothesis
– An increase in accepted COVID-19 ECMO referrals via changes to
screening protocols allows for increased treatment and improved
outcomes.

• Objectives
– Evaluate screening criteria for ECMO patients during COVID-19
– Determine if there is fair evaluation of the medically ill without bias
– Potential liberalization of screening criteria

Approach
•

Population: ECMO referrals between March-October 2020

•

Outcomes

•

–

Accepted or decline referral

–

Patient disposition

–

Survival length

Contacting the referring physician
– Inquire about patient status before referral
– Process of referring patients
– Possible referral to another hospital if declined

•

Analysis of accepted and declined patients within established window
– Survival or death
– Hospitalization duration and ECMO treatment duration
– Reason for declination

Results
Figure 1. Overall Patient Classification
Total Patient
Referrals
N = 64

Accepted/Admitted

Declined

Other

N = 25

N = 33

N=6

• 64 total patient referrals between March 2020 and October 2020

Results
Table 1. Mortality of Classified Patients within 30 days
Patient
Classification

Alive <30 days

Deceased <30 days

Deceased >30 days

Accepted

13

11

1

Declined

10

23

0

• Further separation of patient population allows for identification of
possible missed patients
• Severe organ dysfunction, underlying co-morbidities, and previous
mechanical ventilation limited acceptable patients

Results
• 9 of the surviving patient group were discharged in
fair-good disposition
• Majority of admitted patients were placed on VVECMO (63%)
• Mean age
– Declined patients = 47

– Accepted patients = 56

• Strongest predictors of mortality
– Age, chronic respiratory disease, VA-ECMO use, ECMO
duration, acute kidney injury

Conclusions
• ECMO is a useful intervention for increasing the survival rate of
COVID-19 patients
– Reserved for refractory cases of respiratory distress

• Current post-ECMO patient outcomes match the national
average
• Expansion of criteria to allow earlier ECMO implementation can
improve patient mortality
• Continued use of ECMO for accepted patients will decrease
mortality of ARDS due to COVID-19
• A major limitation was the collection of information on declined
patients

Future Directions
• Long-term outcomes of patients surviving
ECMO support
– Related to age, ECMO duration, initial disposition

• Racial disparities and equitable selection of
ECMO patients
• Use of ECMO earlier in treatment course for
patients with COVID-19
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